Merus (NASDAQ:MRUS) Receives $85.64 Average PT from Brokerages

Shares of Merus (NASDAQ:MRUS) have received a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. Twelve analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $85.64.

A number of brokerages recently commented on MRUS. Citigroup raised their price target on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. The Goldman Sachs Group started coverage on shares of Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $109.00 price target (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price objective on shares of Merus in a research report on Monday, December 9th. Finally, UBS Group assumed coverage on Merus in a research report on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price for the company.

Merus Trading Up 0.5 %

Shares of NASDAQ:MRUS opened at $41.30 on Wednesday. The company has a 50-day moving average price of $42.84 and a 200-day moving average price of $48.79. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -10.46 and a beta of 1.10. Merus has a 12 month low of $33.60 and a 12 month high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The business had revenue of $11.77 million for the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, research analysts forecast that Merus will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Several hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC raised its position in shares of Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares during the last quarter. Avior Wealth Management LLC bought a new stake in Merus during the 4th quarter valued at about $76,000. US Bancorp DE purchased a new position in Merus in the third quarter worth about $103,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after buying an additional 489 shares in the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in shares of Merus during the second quarter valued at approximately $237,000. 96.14% of the stock is owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.